HY-100593A Search Results


spiramycin  (MedChemExpress)
90
MedChemExpress spiramycin
AZ is identified as a potential inhibitor of IAV in vitro. A, The flow chart of IAV‐luc assay. B and C, The relative inhibitory rate of on IAV‐luc infection or cell viability in A549 cells treated with candidate drugs (10 μmol/L). D, The relative cell viability in A549 cells treated with AZ (0.03125‐320 μmol/L) for 72 h. E, The relative inhibitory rate of AZ (10 μmol/L), amantadine (10 μmol/L), oseltamivir (10 μmol/L) and ribavirin (10 μmol/L) on IAV‐luc infection in A549 cells. F, The relative inhibitory rate of AZ (10 μmol/L), erythromycin (10 μmol/L), roxithromycin (10 μmol/L), midecamycin (10 μmol/L), <t>spiramycin</t> (10 μmol/L), acetylspiramycin (10 μmol/L), clarithromycin (10 μmol/L) and dirithromycin (10 μmol/L) on IAV‐luc infection in A549 cells. G, The relative inhibitory rate of ethanol or AZ (2.5 or 5 μmol/L) on IAV‐luc infection in HEK 293T/Hela/A549 cells. H, The relative mRNA level of NP in A549 cells treated with ethanol or AZ (2, 10, 50 μmol/L) and infected with WSN (MOI = 0.001 or 0.01) for 12 h. Solvent was treated as Ctrl. I, The dose‐dependent relative inhibitory rate of AZ on WSN/H5N1/H7N9 pseudovirus infection in A549 cells. Solvent (Ethanol, DMSO or H 2 O) was treated as control (Ctrl). All results are representative of three replicate experiments. ns, no significant, * P < .05, ** P < .01, *** P < .001, **** P < .0001
Spiramycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spiramycin/product/MedChemExpress
Average 90 stars, based on 1 article reviews
spiramycin - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


AZ is identified as a potential inhibitor of IAV in vitro. A, The flow chart of IAV‐luc assay. B and C, The relative inhibitory rate of on IAV‐luc infection or cell viability in A549 cells treated with candidate drugs (10 μmol/L). D, The relative cell viability in A549 cells treated with AZ (0.03125‐320 μmol/L) for 72 h. E, The relative inhibitory rate of AZ (10 μmol/L), amantadine (10 μmol/L), oseltamivir (10 μmol/L) and ribavirin (10 μmol/L) on IAV‐luc infection in A549 cells. F, The relative inhibitory rate of AZ (10 μmol/L), erythromycin (10 μmol/L), roxithromycin (10 μmol/L), midecamycin (10 μmol/L), spiramycin (10 μmol/L), acetylspiramycin (10 μmol/L), clarithromycin (10 μmol/L) and dirithromycin (10 μmol/L) on IAV‐luc infection in A549 cells. G, The relative inhibitory rate of ethanol or AZ (2.5 or 5 μmol/L) on IAV‐luc infection in HEK 293T/Hela/A549 cells. H, The relative mRNA level of NP in A549 cells treated with ethanol or AZ (2, 10, 50 μmol/L) and infected with WSN (MOI = 0.001 or 0.01) for 12 h. Solvent was treated as Ctrl. I, The dose‐dependent relative inhibitory rate of AZ on WSN/H5N1/H7N9 pseudovirus infection in A549 cells. Solvent (Ethanol, DMSO or H 2 O) was treated as control (Ctrl). All results are representative of three replicate experiments. ns, no significant, * P < .05, ** P < .01, *** P < .001, **** P < .0001

Journal: Cell Proliferation

Article Title: Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

doi: 10.1111/cpr.12953

Figure Lengend Snippet: AZ is identified as a potential inhibitor of IAV in vitro. A, The flow chart of IAV‐luc assay. B and C, The relative inhibitory rate of on IAV‐luc infection or cell viability in A549 cells treated with candidate drugs (10 μmol/L). D, The relative cell viability in A549 cells treated with AZ (0.03125‐320 μmol/L) for 72 h. E, The relative inhibitory rate of AZ (10 μmol/L), amantadine (10 μmol/L), oseltamivir (10 μmol/L) and ribavirin (10 μmol/L) on IAV‐luc infection in A549 cells. F, The relative inhibitory rate of AZ (10 μmol/L), erythromycin (10 μmol/L), roxithromycin (10 μmol/L), midecamycin (10 μmol/L), spiramycin (10 μmol/L), acetylspiramycin (10 μmol/L), clarithromycin (10 μmol/L) and dirithromycin (10 μmol/L) on IAV‐luc infection in A549 cells. G, The relative inhibitory rate of ethanol or AZ (2.5 or 5 μmol/L) on IAV‐luc infection in HEK 293T/Hela/A549 cells. H, The relative mRNA level of NP in A549 cells treated with ethanol or AZ (2, 10, 50 μmol/L) and infected with WSN (MOI = 0.001 or 0.01) for 12 h. Solvent was treated as Ctrl. I, The dose‐dependent relative inhibitory rate of AZ on WSN/H5N1/H7N9 pseudovirus infection in A549 cells. Solvent (Ethanol, DMSO or H 2 O) was treated as control (Ctrl). All results are representative of three replicate experiments. ns, no significant, * P < .05, ** P < .01, *** P < .001, **** P < .0001

Article Snippet: Oseltamivir, midecamycin, spiramycin, acetylspiramycin, clarithromycin, dirithromycin, tamoxifen, fluvastatin, fluoxetine and clemastine were obtained from MedChemExpress.

Techniques: In Vitro, Infection, Solvent, Control

AZ has antiviral activity against SARS‐CoV‐2 pseudovirus in vitro. A, The infectivities of SARS‐CoV and SARS‐CoV‐2 pseudovirus in WT and human ACE2 stably expressed HEK293T cells. B, The relative inhibitory rate of AZ (10 μmol/L), erythromycin (10 μmol/L), roxithromycin (10 μmol/L), midecamycin (10 μmol/L), spiramycin (10 μmol/L), acetylspiramycin (10 μmol/L), clarithromycin (10 μmol/L), dirithromycin (10 μmol/L), chloroquine (CQ, 10 μmol/L) and NH 4 Cl (10 mmol/L) on SARS‐CoV‐2 pseudovirus infection in HEK293T‐ACE2 cells. C, The relative cell viability of HEK293T‐ACE2 cells treated with AZ (0.15625‐160 μmol/L) for 72 h. D‐G, The relative inhibitory rate on SARS‐CoV‐2, SARS‐CoV, VSV and Ebola pseudovirus infection in HEK293T‐ACE2 cells treated with AZ (0.625‐10 μmol/L). H, The relative inhibitory rate on SARS‐CoV‐2 pseudovirus infection in Caco2 cells treated with AZ (0.625‐10 μmol/L). I, The relative inhibitory rate on WT and mutant SARS‐CoV‐2 pseudovirus infection in HEK293T‐ACE2 cells treated with AZ (2 and 10 μmol/L). Solvent was treated as Ctrl. Experiments were repeated twice. ns, no significant, * P < .05, ** P < .01, *** P < .001, **** P < .0001

Journal: Cell Proliferation

Article Title: Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

doi: 10.1111/cpr.12953

Figure Lengend Snippet: AZ has antiviral activity against SARS‐CoV‐2 pseudovirus in vitro. A, The infectivities of SARS‐CoV and SARS‐CoV‐2 pseudovirus in WT and human ACE2 stably expressed HEK293T cells. B, The relative inhibitory rate of AZ (10 μmol/L), erythromycin (10 μmol/L), roxithromycin (10 μmol/L), midecamycin (10 μmol/L), spiramycin (10 μmol/L), acetylspiramycin (10 μmol/L), clarithromycin (10 μmol/L), dirithromycin (10 μmol/L), chloroquine (CQ, 10 μmol/L) and NH 4 Cl (10 mmol/L) on SARS‐CoV‐2 pseudovirus infection in HEK293T‐ACE2 cells. C, The relative cell viability of HEK293T‐ACE2 cells treated with AZ (0.15625‐160 μmol/L) for 72 h. D‐G, The relative inhibitory rate on SARS‐CoV‐2, SARS‐CoV, VSV and Ebola pseudovirus infection in HEK293T‐ACE2 cells treated with AZ (0.625‐10 μmol/L). H, The relative inhibitory rate on SARS‐CoV‐2 pseudovirus infection in Caco2 cells treated with AZ (0.625‐10 μmol/L). I, The relative inhibitory rate on WT and mutant SARS‐CoV‐2 pseudovirus infection in HEK293T‐ACE2 cells treated with AZ (2 and 10 μmol/L). Solvent was treated as Ctrl. Experiments were repeated twice. ns, no significant, * P < .05, ** P < .01, *** P < .001, **** P < .0001

Article Snippet: Oseltamivir, midecamycin, spiramycin, acetylspiramycin, clarithromycin, dirithromycin, tamoxifen, fluvastatin, fluoxetine and clemastine were obtained from MedChemExpress.

Techniques: Activity Assay, In Vitro, Stable Transfection, Infection, Mutagenesis, Solvent